VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1VRTX - US92532F1003 - Common Stock
1VRTX.MI Key Statistics, Chart & Performance
The current stock price of 1VRTX.MI is 334.7 EUR. In the past month the price decreased by -11.72%.
1VRTX.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.26 | 47.47B | ||
| 1AE.DE | ARGENX SE | 72.26 | 47.47B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.87B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.34B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.79B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 7.56 | 987.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 881.38M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 678.11M | ||
| IVA.PA | INVENTIVA SA | N/A | 659.01M |
Related stock screener links
About 1VRTX.MI
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / 1VRTX.MI FAQ
Can you describe the business of VERTEX PHARMACEUTICALS INC?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Can you provide the latest stock price for VERTEX PHARMACEUTICALS INC?
The current stock price of 1VRTX.MI is 334.7 EUR. The price decreased by -0.61% in the last trading session.
Does VERTEX PHARMACEUTICALS INC pay dividends?
1VRTX.MI does not pay a dividend.
What is the ChartMill rating of VERTEX PHARMACEUTICALS INC stock?
1VRTX.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (1VRTX.MI)?
The PE ratio for VERTEX PHARMACEUTICALS INC (1VRTX.MI) is 23.19. This is based on the reported non-GAAP earnings per share of 14.43 and the current share price of 334.7 EUR.
Can you provide the ownership details for 1VRTX stock?
You can find the ownership structure of VERTEX PHARMACEUTICALS INC (1VRTX.MI) on the Ownership tab.
1VRTX.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1VRTX.MI.
1VRTX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1VRTX.MI. 1VRTX.MI gets an excellent profitability rating and is at the same time showing great financial health properties.
1VRTX.MI Financial Highlights
Over the last trailing twelve months 1VRTX.MI reported a non-GAAP Earnings per Share(EPS) of 14.43. The EPS increased by 7966.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.86% | ||
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0 |
1VRTX.MI Forecast & Estimates
39 analysts have analysed 1VRTX.MI and the average price target is 416.5 EUR. This implies a price increase of 24.44% is expected in the next year compared to the current price of 334.7.
For the next year, analysts expect an EPS growth of 6256.61% and a revenue growth 10.03% for 1VRTX.MI